Cite

    Reinisch, W. et al. (2006). A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn's disease. Gut. 55 (8), pp. 1138-1144. [Online].